Shilpa Medicare introduces its hybrid CDMO at DCAT 2025, offering a dual-service model with tailored development partnerships and exclusive B2B licensing, enabling pharma companies to accelerate market entry while leveraging Shilpa’s expertise in oncology, biologics, and peptide manufacturing.